Immobilized Endoglycosidase Fusion Protein and Use Thereof
Summary
USPTO published patent application US20260108614A1 on April 23, 2026, covering a method for preparing site-specific antibody-drug conjugates using an immobilized endoglycosidase fusion protein. The method enables covalent attachment of oxazoline oligosaccharides to antibodies at N-glycosylation sites in the Fc region under enzymatic catalysis. The application also discloses the endoglycosidase fusion protein with Halo tag and/or His tag, an immobilized version on a support, and a prepacked column for antibody conjugate purification. Inventors: Cao LV, Jinduo YUAN, Gang QIN, Meijun XIONG. Application No. 19249408, filed June 25, 2025.
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108614A1 disclosing a method for site-specific antibody-drug conjugate preparation based on N-glycosylation sites in antibody Fc regions. The method uses an immobilized endoglycosidase with glycosyltransferase activity to catalyze covalent attachment of oxazoline oligosaccharide donors to GlcNAc-containing antibodies. The application also covers the endoglycosidase fusion protein (with Halo tag and/or His tag), an immobilized version on a support, and a prepacked column for conjugate purification.
Affected parties include pharmaceutical and biotechnology companies engaged in antibody-drug conjugate development, as well as manufacturers of biopharmaceutical manufacturing equipment. The disclosed method may offer advantages in controlled drug-to-antibody ratios and glycan remodeling for ADC production, potentially impacting development strategies for targeted cancer therapeutics and other conjugate-based drugs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF
Application US20260108614A1 Kind: A1 Apr 23, 2026
Inventors
Cao LV, Jinduo YUAN, Gang QIN, Meijun XIONG
Abstract
The present disclosure provides a method for preparing an antibody-drug conjugate, wherein the antibody-drug conjugate is subjected to site-specific conjugation, based on an N-glycosylation site in an Fc region of an antibody, and the method includes the steps of: (1) providing a donor containing oxazoline oligosaccharide, an antibody containing a GlcNAc motif, and an immobilized endoglycosidase with glycosyltransferase activity; (2) covalently attaching the activated donor containing the oxazoline oligosaccharide to the antibody containing the GlcNAc motif under the catalysis of the endoglycosidase. The present disclosure further relates to an endoglycosidase fusion protein, including the endoglycosidase, a Halo tag, and/or a His tag that are covalently attached. The present disclosure further relates to an immobilized endoglycosidase fusion protein obtained by immobilizing the endoglycosidase fusion protein on a support, and a prepacked column filled with the immobilized fusion protein, as well as use of the immobilized endoglycosidase fusion protein for purification of an antibody conjugate.
CPC Classifications
A61K 47/549 A61K 47/22 A61K 47/26 A61K 47/545 A61K 47/68 C12N 9/2402 C07K 2317/41 C07K 2317/52
Filing Date
2025-06-25
Application No.
19249408
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.